Amyris announces jv partnership with immunitybio for next generation covid-19 rna vaccine

Emeryville, calif., nov. 8, 2021 /prnewswire/ -- amyris, inc. (nasdaq: amrs), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its lab-to-markettm operating platform, today announced it has entered into a 50:50 joint venture arrangement with immunitybio, inc. (nasdaq: ibrx), a clinical-stage immunotherapy company, to accelerate the commercialization of a leading next-generation covid-19 vaccine.
AMRS Ratings Summary
AMRS Quant Ranking